 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
August 01, 2012
Genentech, 23andMe Seek Participants for Study on Consumer-Driven GWAS Model
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- FDA's ODAC Not Swayed by Genentech's Biomarker Strategy to ID Best Responders to Avastin
June 29, 2011 / Pharmacogenomics Reporter - Genentech Gets Public Hearing on Avastin, but Remains Coy on Discussing PGx Data
March 2, 2011 / Pharmacogenomics Reporter - FDA Rejects Avastin as Breast Cancer Drug; Genentech to Conduct New Trial to ID Best Responders
November 30, 2011 / Pharmacogenomics Reporter - New VEGF Biomarker Data Illustrates Complexities of Personalizing Anti-Angiogenic Drugs
September 28, 2011 / Pharmacogenomics Reporter - NICE Agrees With FDA in Pulling Avastin's Indication for Metastatic Breast Cancer
February 23, 2011 / Pharmacogenomics Reporter